India to review COVID 19 vaccines after blood clot issues

The government is looking at all adverse proceedings, "particularly serious adverse events like deaths and hospitalisation".

India has decided to conduct an in-depth review of post-vaccination side-effects from the Oxford-AstraZeneca coronavirus vaccine. AstraZeneca, which is being locally developed by Serum Institute of India (SII), was approved for emergency use authorisation along with Bharat Biotech's Covaxin by the Drugs Controller General of India (DCGI) earlier this year.


The news came after several countries had suspended rollout of AstraZeneca shot over blood clot fears; but still now no cases of blood clots have been reported so far in the country. Countries like Austria, Estonia, Latvia, Lithuania and Luxemburg have withdrawn the use of one batch of Astrazeneca vaccine, while others have suspended the use of all its supply for two weeks, pending investigations. As per reports, at least 22 recipients of AstraZeneca had developed coagulation disorders and pulmonary embolism in various European countries


NK Arora, member of the National Task Force on COVID-19, said that the government is looking at all adverse proceedings, "particularly serious adverse events like deaths and hospitalisation". He also said that there is no immediate concern as the "number of adverse events in the country is very low", adding that only 60 "coincidental" deaths have been reported so far.


World Health Organization has said there was no reason to stop using AstraZeneca’s vaccine. Its vaccines advisory committee was looking at safety data and WHO stressed that no link had been established between the vaccines and clotting.

India Scanner News Network

Leave a comment